Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Regarding information being kept

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 02, 2024 10:10am

134 Views

Post# 36249854

RE:RE:RE:Regarding information being kept

ONCY's reference to US$ 2.4 Billion only pertains to their projected 5th year annual peak sales for pelareorep in 3rd line HR+/HER2- metastatic breast cancer indication alone. It doesn't reflect projected peak sales for the other indications that ONCY is pursuing in PDAC and anal cancer, for example.

Nor does the US$ 2.4 Billion represent the full value of ONCY on an acquisition of the company.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China